Category Archives: Parkinson’s Treatment

Public release date: 26-Sep-2013 [ | E-mail | Share ] Contact: Mary Beth O'Leary moleary@cell.com 617-397-2802 Cell Press Induced pluripotent stem cells (iPSCs) taken from a patient hold great therapeutic potential for many diseases. However, studies in rodents have suggested that the body may mount an immune response and destroy cells derived from iPSCs. New research in monkeys refutes these findings, suggesting that in primates like us, such cells will not be rejected by the immune system. In the paper, publishing September 26 in the ISSCR's journal Stem Cell Reports, published by Cell Press, iPSCs from nonhuman primates successfully developed into the neurons depleted by Parkinson's disease while eliciting only a minimal immune response. The cells therefore could hold promise for successful transplantation in humans. iPSCs are cells that have been genetically reprogrammed to an embryonic stem-cell-like state, meaning that they can differentiate into virtually any of the body's different cell types. iPSCs directed to differentiate into specific cell types offer the possibility of a renewable source of replacement cells and tissues to treat ailments, including Parkinson's disease, spinal cord injury, heart disease, diabetes, and arthritis. Studies in rodents have suggested that iPSC-derived cells used for transplantation may be rejected … Continue reading →

From October 1-4, 2013 MONTREAL, Sept. 25, 2013 /CNW Telbec/ - If you're in Montreal at the beginning of October, chances are high that you will run into someone with Parkinson's. From October 1 to 4, Montreal will welcome the Parkinson's community when the city hosts the third World Parkinson Congress (WPC). More than 3,500 participants from over 60 countries are expected to attend this major event at the Palais des congrs, generating more than $6.4 million in economic spinoffs for our city. A great deal of effort has been put into making Montreal "Parkinson's ready" and now Montrealers are encouraged to welcome the delegates. As the only international forum that brings together world renowned neuroscientists, people living with Parkinson's, their caregivers, advocates, medical and healthcare professionals and dedicated researchers, the WPC requires years of preparation and collaboration between local and global organizations. In order to be ready to welcome such an important meeting and its delegates, many of whom live with Parkinson's disease, Tourisme Montral has worked hand in hand with Parkinson Society Qubec, Parkinson Society Canada, the World Parkinson Coalition and many other partners. Because the tourism industry, and front of house staff, is expected to have contact … Continue reading →

TORONTO, ONTARIO--(Marketwired - Sep 26, 2013) - More than 3,000 people from around the world will gather in Montreal, Canada October 1-4 for the 3rd World Parkinson Congress (WPC), a first for Canada. This forum brings together the global Parkinson's community and leading neuroscientists who will share the latest discoveries, treatments and programs for and with people living with Parkinson's disease. "World Parkinson Congress puts people with Parkinson's at the forefront. Individuals come together to exchange research and ideas with a shared goal to improve the quality of life for people with Parkinson's. Parkinson Society Canada is proud to welcome the global Parkinson's community and to contribute to the conversations," says Joyce Gordon, President and CEO, Parkinson Society Canada. What makes the WPC triennial event unique is people with Parkinson's, care partners, health professionals, policy makers, scientists and organizations like Parkinson Society Canada are all represented in the interactive sessions taking place over four days. Not only will participants learn about a broad range of topics including risk factors, exercise and tips and programs for care partners, but also people with Parkinson's will learn from each other. That's why the new Parkinson Buddies Program, a contemporary pen-pal program which partners … Continue reading →

MONTREAL, Sept. 26, 2013 /PRNewswire/ --Nearly 3,500 representatives of the international Parkinson's community will attend the World Parkinson Congress (WPC), taking place at the Palais des Congres in Montreal, from October 1 to 4, 2013. This triennial event brings together world renowned neuroscientists, people living with Parkinson's, caregivers, advocates, and medical and healthcare professionals. The conference is led by the World Parkinson Coalition in collaboration with over 160 partner organizations including Parkinson Society Canada. (Logo: http://photos.prnewswire.com/prnh/20130926/NY86929LOGO ) "The World Parkinson Congress acts as a Parkinson's brainstorming session," said Jon Stoessl, MD, Professor and Head of Neurology and Director of the Pacific Parkinson's Research Centre at UBC and co-chair of the WPC Steering Committee. "It offers a unique opportunity for leading Parkinson's researchers to share information and ideas with other scientists, people with Parkinson's and care providers." For four days, experts will discuss a range of cutting-edge subjects, including cell- and gene-based therapy strategies, the latest in brain imaging, the use of optogenetics to study Parkinson's, advances in understanding the non-motor symptoms of Parkinson's disease, and the use of dance as a therapy. "There is exciting work going on in Parkinson's research throughout the world," said David Burn, MD, Director of … Continue reading →

You would probably never think of going to a hospital to watch the premiere of a TV show. But on Thursday, St. Paul's Bethesda Hospital is hosting a viewing party for NBC's new comedy "The Michael J. Fox Show." Sponsored by the hospital's Capistrant Center for Parkinson's Disease and Movement Disorders, the event is open to patients and the public. Thanks to his fame, Fox has become the face of Parkinson's disease since publicly disclosing his diagnosis in 1998. On his new show, Parkinson's is front and center. Fox plays Mike Henry, a New York TV anchor who years earlier had quit his job to spend more time with his family after being diagnosed with Parkinson's. In the first episode, Fox decides to re-enter the workforce and get back Michael J. Fox as Mike Henry. (Photo by: Eric Liebowitz/NBC) In a video posted on NBC.com, Fox addressed people who have asked him how he could make fun of the disease. "We're not making fun of Parkinson's; we're examining a life, a life that has Parkinson's and just how one guy deals with it, one guy's experience with it," Fox said. "And my experience is to deal with things through humor. … Continue reading →

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has announced that US District Court for the District of New Jersey has ruled in its favor in the Azilect patent infringement case against Mylan Inc. (Nasdaq: MYL). The court has upheld the validity of Tevas patent for the Parkinson's disease treatment, and Teva anticipates the court will enter judgment that prevents Mylan from launching its generic version of Azilect until Tevas patent expires in 2017. Teva sued Mylan in October 2010, and later filed similar patent infringement suits against Watson Pharmaceuticals (now part of Actavis Inc. (NYSE: ACT)), Canada's Apotex Inc., India's Orchid Chemicals & Pharmaceuticals Ltd. (BSE: 524372), and Novartis AG (NYSE:NVS; LSE: NOV; SWX: NOVZ) generics unit Sandoz. Teva settled with Watson, Apotex, and Orchid earlier this year, and Sandoz has agreed that it will be bound by the final ruling in the Mylan case. US Food and Drug Administration (FDA) records show that it has approved in the past few weeks three generic versions of Teva's Azilect. However, the FDA approval only clears one of the hurdles - the regulatory hurdle - en route to market. There is also the legal aspect of patent protection. As is usual … Continue reading →

These days, it's hard for Linda Ronstadt to get around without her forearm crutches. The debilitating effects of Parkinson's disease require her to relax for a few minutes before starting an interview. But once she's ready, the 67-year-old has full command of her voice, even though she's no longer able to sing. Ronstadt's voice was one of music's great treasures, anchoring hits such as When Will I Be Loved and You're No Good and hop-scotching across genres including pop, rock, jazz and folk. She's sold more than 30 million albums. While her singing voice has been silenced, she's expressing herself in her memoir, Simple Dreams. It touches on the many milestones in her career, though more personal matters, like her high-profile romances with Jerry Brown and others, are briefly mentioned or not at all. It also doesn't discuss her Parkinson's diagnosis, which came after the book was written. Ronstadt spoke to The Associated Press about the book and battling the degenerative disease, among other topics. --- Q: HOW HAVE YOU ADAPTED TO LIVING WITH PARKINSON'S? A: I have to ask people to do things for me that are hard. That's been the hardest thing, I think. It's harder to go … Continue reading →

These days, it's hard for Linda Ronstadt to get around without her forearm crutches. The debilitating effects of Parkinson's disease require her to relax for a few minutes before starting an interview. But once she's ready, the 67-year-old singer has full command of her voice, even though she's no longer able to sing. Play Video Ronstadt's voice was one of music's great treasures, anchoring hits like "When Will I Be Loved" and "You're No Good" and hop-scotching across genres including pop, rock, jazz and folk. She's sold more than 30 million albums. While her singing voice has been silenced, she's expressing herself in her memoir, "Simple Dreams." It touches on the many milestones in her career, though more personal matters, like her high-profile romances with Jerry Brown and others, are briefly mentioned or not at all. It also doesn't discuss her Parkinson's diagnosis, which came after the book was written. This week, Ronstadt spoke to The Associated Press about the book and battling the degenerative disease, among other topics. AP: How have you adapted to living with Parkinson's? Ronstadt: I have to ask people to do things for me that are hard. That's been the hardest thing, I think. It's … Continue reading →

Home Mail News Sports Finance Weather Games Groups Answers Screen Flickr More omg! Shine Movies Music TV Health Shopping Travel Autos Homes Mobile Yahoo News Search News Search Web Sign In Mail Help Account Info Help Suggestions Yahoo News Home Video Photos GMA Year in Review Odd Comics Travel Opinion Trending Now Who Knew? Weather The Upbeat U.S. U.S. Video GMA Education Religion Crimes and Trials Local Contributor Network Year In Review World World Video Middle East Europe Latin America Africa Asia Canada Australia/Antarctica Business Video Exclusives Today's Markets Stocks Personal Finance Marketplace Entertainment Video Clinton Concert Celebrity TV Movies Music Fashion Books Arts Theater Dear Abby Comics Odd News Sports Video NFL MLB NBA NCAAF NCAAB Soccer Cycling NHL Tennis Golf Boxing Motor Sports MMA Olympics Tech Gadgets Wireless Apple Social Media Security Open Source Gaming Apps This Could Be Big Upgrade Your Life Politics Remake America The Issues Women and Politics Press Releases Video Science Science Video Weather News Space / Astronomy Pets Dinosaurs / Fossils Biotech Energy Green Health Video Weight Loss Cancer Sexual Health Medications/Drugs Parenting/Kids Seniors/Aging Diseases/Conditions Blogs The Sideshow Katie's Take Power Players This Could Be Big Newsmakers Trending Now The Upbeat Who Knew? … Continue reading →

Living Cell Technologies (LCT) Limited today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL - a potential treatment for Parkinsons disease. The pioneering brain surgery was conducted yesterday at Auckland City Hospital and the patient has so far recovered well, although the full impact of the surgical procedure will not be known for several days. The Phase I clinical trial is an open label investigation of the safety and clinical effect of NTCELL in four people who have been diagnosed with Parkinsons disease for at least four years. The first patient will now be monitored for two months to confirm no serious adverse safety events. At that time, the independent data safety monitoring board (DSMB) will consider the safety data and advise if the implants for the remaining three patients can proceed. The trial Principal Investigator is Dr Barry Snow (MBChB, FRACP, FRCPC), an internationally recognised clinician and researcher in Parkinsons disease who leads the Auckland Movement Disorders Clinic at the Auckland District Health Board. "The team is pleased with how well the patient tolerated the procedure itself," says Dr Snow. "The surgery is relatively straightforward in … Continue reading →